STAT3-IN-39, identified by its CAS number 3037596-35-0, is a small molecule inhibitor specifically targeting the Signal Transducer and Activator of Transcription 3 (STAT3) pathway, which plays a crucial role in various cellular processes, including cell growth, survival, and differentiation. This compound is of particular interest in cancer research due to its potential to disrupt aberrant STAT3 signaling often associated with tumor progression and immune evasion. STAT3-IN-39 exhibits characteristics typical of small molecule inhibitors, such as moderate molecular weight and specific functional groups that facilitate binding to the STAT3 protein. Its mechanism of action involves inhibiting the phosphorylation and dimerization of STAT3, thereby preventing its translocation to the nucleus and subsequent transcription of target genes involved in oncogenesis. In preclinical studies, STAT3-IN-39 has shown promise in reducing tumor growth and enhancing the efficacy of other therapeutic agents. Further research is ongoing to fully elucidate its pharmacokinetics, bioavailability, and potential therapeutic applications in oncology and other diseases linked to dysregulated STAT3 activity.

STAT3-IN-39

3037596-35-0: STAT3-IN-39, identified by its CAS number 3037596-35-0, is a small molecule inhibitor specifically targeting the Signal Transducer and Activator of Transcription 3 (STAT3) pathway, which plays a crucial role in various cellular processes, including cell growth, survival, and differentiation. This compound is of particular interest in cancer research due to its potential to disrupt aberrant STAT3 signaling often associated with tumor progression and immune evasion. STAT3-IN-39 exhibits characteristics typical of small molecule inhibitors, such as moderate molecular weight and specific functional groups that facilitate binding to the STAT3 protein. Its mechanism of action involves inhibiting the phosphorylation and dimerization of STAT3, thereby preventing its translocation to the nucleus and subsequent transcription of target genes involved in oncogenesis. In preclinical studies, STAT3-IN-39 has shown promise in reducing tumor growth and enhancing the efficacy of other therapeutic agents. Further research is ongoing to fully elucidate its pharmacokinetics, bioavailability, and potential therapeutic applications in oncology and other diseases linked to dysregulated STAT3 activity.

STAT3-IN-39 (compound 10K) is an orally active inhibitor of STAT3, demonstrating effective inhibition of STAT3 phosphorylation with an IC50 of 0.47 μM in NIH-3T3 cells. It hinders TGF-β1-induced fibrotic responses and prevents epithelial-mesenchymal transition in A549 cells. STAT3-IN-39 is applicable for research related to idiopathic pulmonary fibrosis.

CAS 3037596-35-0

STAT3-IN-39

STAT3-IN-39

Ref: TM-T203317